Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 7/20 | 0.44 |
| ▸ | KMO | O15229 | 4/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | CCKAR | P32238 | 3/20 | 0.41 |
| ▸ | MT-CO1 | P00395 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | ADH5 | P11766 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25208397 | 1.00 | DHODH (0.44) | DHODHKMOGRM2CCKARMT-CO1 | |
| SCHEMBL25208970 | 0.89 | KMO (0.57) | DHODHKMOHDAC1PDK1ADH5 | |
| SCHEMBL32680032 | 0.89 | KMO (0.57) | DHODHKMOHDAC1PDK1ADH5 | |
| SCHEMBL25245579 | 0.86 | KMO (0.46) | DHODHKMOGRM2CCKARMT-CO1 | |
| SCHEMBL30036755 | 0.83 | SLC22A12 (0.43) | KMOPDK1 | |
| SCHEMBL25552031 | 0.83 | SLC22A12 (0.43) | KMOPDK1 | |
| SCHEMBL30037130 | 0.83 | MBNL1 (0.47) | DHODHKMOPDK1 | |
| SCHEMBL25552003 | 0.83 | MBNL1 (0.47) | DHODHKMOPDK1 | |
| SCHEMBL25244771 | 0.81 | DHODH (0.47) | DHODHKMOADH5 | |
| SCHEMBL30037152 | 0.78 | KMO (0.42) | DHODHKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565490-B2 | Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12565490-B2 | Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease | RIPK1, RIPK4, RIPK2 | DHODH 4056/4885KMO 2319/4885GRM2 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.